Pfizer: A Rewards Program for Government Doctors

In the Pfizer FCPA case, Pfizer Inc. agreed to pay $26,339,944 to settle Securities and Exchange Commission allegations that subsidiaries bribed government doctors and disguised the payments as business expenses. The alleged incentives included points earned for prescriptions and bonuses tied to hospital purchases. If you worked in pharmaceutical sales, finance, or compliance, the connection between the doctor’s benefit and the company’s sales may be the part you recognize.

The SEC announced the settlement on August 7, 2012, alongside a separate settlement with Wyeth, which Pfizer had acquired. The Justice Department announced a criminal agreement with Pfizer H.C.P., an indirect wholly owned subsidiary. These Foreign Corrupt Practices Act proceedings concerned different companies and different accounts of the conduct: Pfizer H.C.P. admitted bribery, while the Commission described allegations against Pfizer Inc. and Wyeth.

What Pfizer H.C.P. Admitted

Under its deferred prosecution agreement, Pfizer H.C.P. admitted paying more than $2 million in bribes between 1997 and 2006 and making more than $7 million in resulting profits, according to the Justice Department’s announcement. The admitted payments went to government officials in Bulgaria, Croatia, Kazakhstan, and Russia.

In announcing Pfizer H.C.P.’s criminal information and deferred prosecution agreement, the Justice Department identified hospital administrators, members of regulatory and purchasing committees, and other healthcare professionals as recipients. The decisions Pfizer H.C.P. sought to influence included approval and registration of products, the award of pharmaceutical tenders, and sales.

The same announcement described sham consulting contracts, an exclusive distributorship, improper travel, and cash payments as mechanisms for influencing those decisions. That puts familiar commercial records at the center of the case: what service a consultant supposedly provided, why a distributor was selected, and what the company expected from a trip or payment.

Why Prescriptions and Formularies Matter

In pharmaceutical bribery, the person writing a prescription can also hold public authority. A March 2015 Securities and Exchange Commission enforcement speech on the pharmaceutical industry explained that sales representatives regularly deal with doctors, pharmacists, and administrators at public hospitals who often decide which products those institutions buy. It identified payments for prescriptions and payments to get drugs onto an approved list, or formulary, as recurring mechanisms.

That business setting makes the alleged Pfizer incentives particularly revealing. According to the Commission’s account of its complaint, Pfizer employees in China invited doctors with high prescribing volumes to meetings with extensive recreation and entertainment, rewarding past sales or prescriptions. A separate points program allegedly let government doctors accumulate points according to the number of Pfizer prescriptions they wrote and exchange them for medical books, cell phones, tea sets, and reading glasses.

The alleged program made prescribing volume the basis for a personal reward. We see the absurdity in treating a government doctor’s prescriptions like purchases on a customer loyalty card: the doctor earned the gift, while the prescription concerned a patient’s treatment.

In Croatia, the Securities and Exchange Commission alleged that employees offered a bonus program to doctors holding senior positions in government health care institutions. Once a doctor agreed to use Pfizer products, a percentage of the value bought by the institution allegedly returned to the doctor as cash, international travel, or free products. The institution’s purchase supplied the measure for the doctor’s benefit.

Novartis Hellas later admitted in its 2020 deferred prosecution agreement that congress sponsorship for Greek public-sector ophthalmologists was tied to increased Lucentis prescribing. The Commission’s separate Novartis order recorded how a manager planned to describe that exchange to a doctor:

The words make the bargain explicit. For an insider, the useful connection is between the benefit and the prescribing expectation: who chose the doctor, what sales were expected, and how the company tracked the return.

The Pfizer SEC Allegations Reached the Expense Accounts

The Securities and Exchange Commission alleged improper payments by Pfizer subsidiaries dating as far back as 2001. The allegations covered Bulgaria, China, Croatia, the Czech Republic, Italy, Kazakhstan, Russia, and Serbia. Its complaint account traced those payments to regulatory and formulary approvals, sales, and increased prescriptions. It also described how the subsidiaries allegedly concealed the transactions in their accounting records.

The alleged disguises included marketing, travel and entertainment, clinical trials, and freight expenses. A finance employee could therefore encounter the alleged scheme as a routine expense entry, while a sales employee knew which doctor or institution the spending was intended to influence. Connecting those views is the point of examining the subsidiary’s books and the business behind them.

The same gap between a payment and its accounting label appeared in Fresenius Medical Care. In its 2019 order, the SEC found that employees at a Saudi subsidiary cashed checks and handed the money to its general manager, while the transactions appeared in the books as project marketing expenses and collection commissions. Those books were consolidated into Fresenius’s accounts.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA examines how managers and employees bypassed controls despite flagged transactions and policies. An approval process and an accurate explanation of a payment are different things, and the people inside the business may know where they diverged.

Wyeth Had Its Own Products, Payments, and Settlement

Wyeth agreed to pay $18,876,624 in its separate Securities and Exchange Commission settlement. The allegations against Wyeth concerned its own subsidiaries, including nutritional-product sales and a shipment held at a port.

Starting at least in 2005, the Securities and Exchange Commission alleged, subsidiaries marketing Wyeth nutritional products in China, Indonesia, and Pakistan bribed government doctors to recommend those products to patients. The alleged benefits included cash, BlackBerrys, other cell phones, and travel incentives. Fictitious invoices allegedly concealed what the payments were for.

In Saudi Arabia, the Commission alleged that a Wyeth subsidiary paid a customs official to release promotional items held at the port. The shipment lacked a required Saudi Arabian Standards Organization Certificate of Conformity. Here, the official decision allegedly being bought was clearance of goods the company wanted for marketing, a different transaction from a doctor’s product recommendation.

The SEC alleged that the Wyeth conduct occurred primarily before, but also after, Pfizer acquired the company in late 2009. That timing connects the sales and invoice records to what happened inside an acquired business.

The Securities and Exchange Commission described Pfizer’s integration of Wyeth’s operations into its compliance program. For someone inside an acquired company, the practical question is whether the old payment practices, invoice descriptions, and approval arrangements actually came under the new controls.

What a Pharmaceutical Insider Would Recognize

The relevant FCPA whistleblower evidence connects the government decision, the benefit, and the explanation entered in the books. In the Pfizer allegations, the prescribing and purchasing figures explained why particular doctors received benefits. In Wyeth’s allegations, invoices concealed payments, while the missing certificate explained why a shipment was stuck.

Someone in sales may know the prescription target behind a sponsored trip or who selected the doctors for a program. Someone in finance may know the invoice, payment approval, and expense category for the same benefit. A distributor or regulatory employee may know which official controlled the tender, product approval, or release of a shipment. Those different views can connect a payment that looks ordinary on its own to the business decision it was intended to buy.

We work with you to assess that connection and the records you know firsthand. Questions about handling documents and protecting your identity belong in that conversation with our whistleblower experts, alongside the transaction itself.

Whistleblower Rewards Follow Their Own Rules

FCPA whistleblower rewards depend on the applicable program and the contribution of the information. We assess that opportunity with you, starting with what your knowledge adds to the case. For fraud against the government, a separate whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Payment Bought

If you know what a doctor’s benefit or a port-clearance payment bought, speak to one of our Whistleblower Experts about what you saw. We work with you to build your strongest FCPA whistleblower case, bring in whistleblower lawyers who understand pharmaceutical sales and foreign-government customers, and stay beside you through the process.